# Luna Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/luna-health

- Industry: Medical Devices & Equipment
- Headquarters: Wilmington, US
- Website: www.lunadiabetes.com
- Total disclosed funding: $24M
- Latest round: Series A (Aug 12, 2025)
- Investors on record: 5

## About

Luna Health, Inc. is a US-based company specializing in automated insulin delivery solutions, focusing on enhancing diabetes management for insulin pen users through innovative technology and seamless user experience. Founded in 2020 in San Diego, US, Luna Health, Inc. develops solutions for diabetes management.  In August 2025, Luna Health, Inc. raised USD 23.62 million in Series A funding led by investor Vensana Capital, with participation from investors Ascensia Diabetes Care Holdings AG, 2468 Ventures, Interlock Capital, and Winklevoss Capital. Investor Swiss Diabetes Venture Fund also participated in the round. Luna Diabetes specializes in automated insulin delivery solutions specifically designed for users of insulin pens. Their flagship product, Luna, operates exclusively during sleep, delivering micro-boluses of insulin to maintain optimal glucose control throughout the night. This innovative technology simplifies nighttime diabetes management, providing users with a seamless experience that allows for uninterrupted rest. The primary market for Luna includes regions with high diabetes prevalence, particularly in the United States and select countries in Europe. Luna Diabetes generates revenue through the sale of its Luna device, positioned as a direct-to-consumer product targeting individuals who use insulin pens. The business model emphasizes consumer engagement, potentially involving subscription services for ongoing support and updates related to the device. Revenue is facilitated through direct sales to consumers, enhancing the purchasing experience, with additional revenue opportunities arising from partnerships with healthcare providers and diabetes management programs. In August 2025, Luna Health, Inc. raised USD 23.6 mn in Series A funding to develop and test a wearable device that automatically adjusts insulin levels overnight for people with diabetes. The company plans to leverage this funding for the upcoming product launch and explore expansion into additional markets in Europe to cater to growing diabetes management needs.

## Funding rounds

- Series A, Aug 12, 2025, $24M — Winklevoss Capital, Ascensia Diabetes Care Holdings AG, Vensana Capital, Serpentine Ventures, Interlock Capital

## Investors

- Winklevoss Capital (https://capitalatlas.ai/funds/winklevoss-capital) — Series A
- Ascensia Diabetes Care Holdings AG — Series A
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series A
- Serpentine Ventures (https://capitalatlas.ai/funds/serpentine-ventures) — Series A
- Interlock Capital — Series A